[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-209072-105":59,"doc-detail-209072-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","health-supervision-for-children-with-neurofibromatosis-type-1-clinical-report-guidance-for-the-clinician-in-rendering-pediatric-care","Health Supervision for Children With Neurofibromatosis Type 1 - Clinical Report Guidance for the Clinician in Rendering Pediatric Care","","Neurofibromatosis type 1 (NF1) is a multisystem inherited disorder affecting the skin and peripheral nervous system, often recognized in early childhood as pigmentary findings emerge. Although clinical expression varies widely and most children show development within normal ranges, some features may appear at birth and many manifestations evolve with age. The report reviews diagnostic criteria, inheritance, major clinical and developmental manifestations, and provides monitoring and intervention guidelines to support health and quality of life while reducing risk of serious complications.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/health-supervision-for-children-with-neurofibromatosis-type-1-clinical-report-guidance-for-the-clinician-in-rendering-pediatric-care/209072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/health-supervision-for-children-with-neurofibromatosis-type-1-clinical-report-guidance-for-the-clinician-in-rendering-pediatric-care/209072.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-05",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"How is NF1 typically recognized by clinicians?","Question",{"text":113,"@type":114},"NF1 is often recognized in early childhood when pigmentary manifestations emerge, reflecting a multisystem pattern involving the skin and peripheral nervous system.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},209072,1788608886,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":132,"language":133,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":134,"faqs":135,"seo_title":136,"seo_description":67,"update_tm":122,"read_time":137},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","CLINICAL REPORT Guidance for the Clinician in Rendering Pediatric Care  \nHealth Supervision for Children With Neurofibromatosis Type 1  \nDavid T. Miller, MD, PhD, FAAP,a Debra Freedenberg, MD, PhD, FAAP,b Elizabeth Schorry, MD,c Nicole J. Ullrich, MD, PhD,d David Viskochil, MD, PhD,e Bruce R. Korf, MD, PhD, FAAP,f COUNCIL ON GENETICS, AMERICAN COLLEGE OF MEDICAL GENETICS AND GENOMICS  \nNeurofibromatosis type 1 (NF1) is a multisystem disorder that primarily involves the skin and peripheral nervous system. Its population prevalence is approximately 1 in 3000 . The condition is usually recognized in early childhood, when pigmentary manifestations emerge. Although NF1 is associated with marked clinical variability, most children affected follow patterns of growth and development within the normal range. Some features of NF1 can be present at birth, but most manifestations emerge with age, necessitating periodic monitoring to address ongoing health and developmental needs and minimize the risk of serious medical complications. In this report, we provide a review of the clinical criteria needed to establish a diagnosis, the inheritance pattern of NF1, its major clinical and developmental manifestations, and guidelines for monitoring and providing intervention to maximize the health and quality of life of a child affected.  \nINTRODUCTION  \nNeurofibromatosis type 1 (NF1) is 1 of the most common inherited genetic conditions, affecting approximately 1 in 3000 individuals.1 NF1 is a multisystem disorder in which some features may be present at birth but most are age-related manifestations. Since the publication of the article“Health Supervision for Children With Neurofibromatosis,” the health supervision and treatment rationale has evolved, necessitating this update.2 In this report, we only address issues concerning the diagnosis and management of NF1, which should not be confused with neurofibromatosis type 2, a separate and distinct disorder that typically presents in childhood and adolescence with cutaneous and vestibular schwannomas and has an incidence of 1 in 33000 and a prevalence of less than 1 in 50000 .1 Most pediatricians and pediatric medical subspecialists follow multiple children with NF1 in their practices, and NF1 has a wide spectrum of health implications. This document seeks to educate and provide guidance for the clinician on the current understanding of the  \nabstract  \naDivision of Genetics and Genomics and dDepartment of Neurology, Harvard Medical School, Harvard University and Boston Children’s Hospital, Boston, Massachusetts; b Texas Department of State Health Services, Austin, Texas; cDivision of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; eDivision of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, Utah; and fDepartment of Genetics, University of Alabama at Birmingham, Birmingham, Alabama  \nDr Miller led the working group, served as liaison between the working group and the American College of Medical Genetics, reviewed and updated literature references, and drafted several sections; Dr Freedenberg served as liaison between the working group and the American Academy of Pediatrics; Drs Schorry, Ullrich, and Viskochil reviewed and updated literature references and drafted several sections; Dr Korf cochaired the working group, reviewed and updated literature references, and drafted several sections; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.  \nCl","cbCaildKf0l7YPri","https://ap.wps.com/l/cbCaildKf0l7YPri","pdf",463024,18,"English","# Introduction\n## Diagnosis and diagnostic criteria\n## Inheritance pattern\n## Major clinical and developmental manifestations\n## Monitoring and intervention guidelines\n# NF1 clinical criteria (NIH Consensus Development Conference)","[{\"question\":\"How is NF1 typically recognized by clinicians?\",\"answer\":\"NF1 is often recognized in early childhood when pigmentary manifestations emerge, reflecting a multisystem pattern involving the skin and peripheral nervous system.\"}]","Health Supervision for Children With Neurofibromatosis Type 1 - Clinical Report Guidance for the Clinician in Rendering Pediatric Care | PDF",45]